Neurocrine Change In Cash vs End Period Cash Flow Analysis

NBIX Stock

USD 136.69 3.64 2.74%

Neurocrine Biosciences financial indicator trend analysis is infinitely more than just investigating Neurocrine Biosciences recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Neurocrine Biosciences is a good investment. Please check the relationship between Neurocrine Biosciences Change In Cash and its End Period Cash Flow accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neurocrine Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

For more information on how to buy Neurocrine Stock please use our How to Invest in Neurocrine Biosciences guide.

Change In Cash vs End Period Cash Flow

Change In Cash vs End Period Cash Flow Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Neurocrine Biosciences Change In Cash account and End Period Cash Flow. At this time, the significance of the direction appears to have weak relationship.

The correlation between Neurocrine Biosciences' Change In Cash and End Period Cash Flow is 0.35. Overlapping area represents the amount of variation of Change In Cash that can explain the historical movement of End Period Cash Flow in the same time period over historical financial statements of Neurocrine Biosciences, assuming nothing else is changed. The correlation between historical values of Neurocrine Biosciences' Change In Cash and End Period Cash Flow is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Change In Cash of Neurocrine Biosciences are associated (or correlated) with its End Period Cash Flow. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when End Period Cash Flow has no effect on the direction of Change In Cash i.e., Neurocrine Biosciences' Change In Cash and End Period Cash Flow go up and down completely randomly.

Correlation Coefficient

0.35

Relationship Direction	Positive
Relationship Strength	Very Weak

View All Relationships

Change In Cash

End Period Cash Flow

Most indicators from Neurocrine Biosciences' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Neurocrine Biosciences current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neurocrine Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

For more information on how to buy Neurocrine Stock please use our How to Invest in Neurocrine Biosciences guide.At this time, Neurocrine Biosciences' Selling General Administrative is fairly stable compared to the past year. Tax Provision is likely to rise to about 63.8 M in 2024, whereas Issuance Of Capital Stock is likely to drop slightly above 22.9 M in 2024.

Neurocrine Biosciences fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Intangible Assets	Short Term Investments	Other Liab	Other Assets
Total Assets		0.19	0.97	0.9	0.99	0.97	0.39	0.47	0.98	0.46	0.99	0.86	0.95	0.97	0.45	0.68	0.63	0.9	0.96	0.94	0.99	0.52	0.87	0.93	0.21	0.79
Short Long Term Debt Total	0.19		0.16	0.35	0.11	0.2	0.39	-0.57	0.21	0.08	0.16	0.02	0.31	0.1	0.59	0.19	0.39	0.46	0.34	0.18	0.22	0.62	0.09	0.3	0.21	0.03
Other Current Liab	0.97	0.16		0.94	0.97	0.96	0.38	0.58	0.98	0.37	0.96	0.86	0.88	0.98	0.35	0.5	0.63	0.82	0.9	0.94	0.95	0.58	0.87	0.88	0.16	0.77
Total Current Liabilities	0.9	0.35	0.94		0.88	0.91	0.58	0.42	0.95	0.23	0.88	0.81	0.86	0.92	0.37	0.41	0.8	0.8	0.89	0.89	0.91	0.81	0.74	0.89	0.23	0.6
Total Stockholder Equity	0.99	0.11	0.97	0.88		0.96	0.32	0.54	0.98	0.43	0.98	0.88	0.92	0.99	0.41	0.62	0.55	0.88	0.91	0.94	0.97	0.46	0.87	0.9	0.21	0.8
Property Plant And Equipment Net	0.97	0.2	0.96	0.91	0.96		0.37	0.57	0.99	0.34	0.98	0.91	0.86	0.96	0.29	0.59	0.62	0.81	0.91	1.0	0.92	0.53	0.81	0.86	0.19	0.74
Net Debt	0.39	0.39	0.38	0.58	0.32	0.37		-0.03	0.43	-0.37	0.36	0.34	0.41	0.38	0.21	0.21	0.78	0.4	0.5	0.36	0.41	0.74	0.13	0.41	0.38	-0.18
Retained Earnings	0.47	-0.57	0.58	0.42	0.54	0.57	-0.03		0.54	0.01	0.53	0.61	0.23	0.58	-0.45	0.02	0.18	0.06	0.3	0.58	0.39	0.02	0.48	0.27	-0.11	0.44
Accounts Payable	0.98	0.21	0.98	0.95	0.98	0.99	0.43	0.54		0.34	0.98	0.9	0.9	0.98	0.34	0.56	0.67	0.84	0.93	0.98	0.95	0.59	0.84	0.9	0.21	0.73
Cash	0.46	0.08	0.37	0.23	0.43	0.34	-0.37	0.01	0.34		0.42	0.1	0.55	0.33	0.52	0.66	0.09	0.5	0.49	0.28	0.49	-0.02	0.63	0.49	-0.27	0.84
Non Current Assets Total	0.99	0.16	0.96	0.88	0.98	0.98	0.36	0.53	0.98	0.42		0.86	0.9	0.96	0.37	0.67	0.58	0.86	0.94	0.97	0.95	0.47	0.86	0.86	0.16	0.78
Non Currrent Assets Other	0.86	0.02	0.86	0.81	0.88	0.91	0.34	0.61	0.9	0.1	0.86		0.74	0.92	0.15	0.39	0.46	0.69	0.75	0.93	0.82	0.41	0.63	0.76	0.43	0.55
Cash And Short Term Investments	0.95	0.31	0.88	0.86	0.92	0.86	0.41	0.23	0.9	0.55	0.9	0.74		0.9	0.63	0.73	0.66	0.96	0.95	0.83	0.98	0.57	0.83	0.98	0.26	0.76
Net Receivables	0.97	0.1	0.98	0.92	0.99	0.96	0.38	0.58	0.98	0.33	0.96	0.92	0.9		0.35	0.52	0.59	0.84	0.89	0.95	0.96	0.53	0.83	0.9	0.27	0.74
Common Stock Shares Outstanding	0.45	0.59	0.35	0.37	0.41	0.29	0.21	-0.45	0.34	0.52	0.37	0.15	0.63	0.35		0.51	0.24	0.74	0.5	0.25	0.52	0.33	0.39	0.57	0.31	0.39
Non Current Liabilities Total	0.68	0.19	0.5	0.41	0.62	0.59	0.21	0.02	0.56	0.66	0.67	0.39	0.73	0.52	0.51		0.4	0.72	0.78	0.56	0.68	0.13	0.64	0.63	0.07	0.63
Other Current Assets	0.63	0.39	0.63	0.8	0.55	0.62	0.78	0.18	0.67	0.09	0.58	0.46	0.66	0.59	0.24	0.4		0.55	0.75	0.6	0.66	0.89	0.44	0.71	0.1	0.29
Other Stockholder Equity	0.9	0.46	0.82	0.8	0.88	0.81	0.4	0.06	0.84	0.5	0.86	0.69	0.96	0.84	0.74	0.72	0.55		0.91	0.78	0.93	0.53	0.75	0.91	0.31	0.69
Total Liab	0.96	0.34	0.9	0.89	0.91	0.91	0.5	0.3	0.93	0.49	0.94	0.75	0.95	0.89	0.5	0.78	0.75	0.91		0.89	0.96	0.62	0.83	0.92	0.2	0.73
Property Plant And Equipment Gross	0.94	0.18	0.94	0.89	0.94	1.0	0.36	0.58	0.98	0.28	0.97	0.93	0.83	0.95	0.25	0.56	0.6	0.78	0.89		0.9	0.51	0.77	0.83	0.22	0.7
Total Current Assets	0.99	0.22	0.95	0.91	0.97	0.92	0.41	0.39	0.95	0.49	0.95	0.82	0.98	0.96	0.52	0.68	0.66	0.93	0.96	0.9		0.56	0.86	0.97	0.26	0.78
Short Term Debt	0.52	0.62	0.58	0.81	0.46	0.53	0.74	0.02	0.59	-0.02	0.47	0.41	0.57	0.53	0.33	0.13	0.89	0.53	0.62	0.51	0.56		0.33	0.64	0.16	0.19
Intangible Assets	0.87	0.09	0.87	0.74	0.87	0.81	0.13	0.48	0.84	0.63	0.86	0.63	0.83	0.83	0.39	0.64	0.44	0.75	0.83	0.77	0.86	0.33		0.79	0.09	0.89
Short Term Investments	0.93	0.3	0.88	0.89	0.9	0.86	0.41	0.27	0.9	0.49	0.86	0.76	0.98	0.9	0.57	0.63	0.71	0.91	0.92	0.83	0.97	0.64	0.79		0.27	0.75
Other Liab	0.21	0.21	0.16	0.23	0.21	0.19	0.38	-0.11	0.21	-0.27	0.16	0.43	0.26	0.27	0.31	0.07	0.1	0.31	0.2	0.22	0.26	0.16	0.09	0.27		-0.14
Other Assets	0.79	0.03	0.77	0.6	0.8	0.74	-0.18	0.44	0.73	0.84	0.78	0.55	0.76	0.74	0.39	0.63	0.29	0.69	0.73	0.7	0.78	0.19	0.89	0.75	-0.14

Click cells to compare fundamentals

Neurocrine Biosciences Account Relationship Matchups

Neurocrine Biosciences fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	1.3B	1.7B	2.1B	2.4B	3.3B	3.4B
Short Long Term Debt Total	817.6M	412.3M	440.4M	262.9M	428.4M	449.8M
Other Current Liab	156.5M	147.1M	194.3M	292M	351.4M	369.0M
Total Current Liabilities	565.3M	186.5M	245.8M	537.7M	654.8M	687.5M
Total Stockholder Equity	636.9M	1.1B	1.4B	1.7B	2.2B	2.3B
Property Plant And Equipment Net	116.2M	127.4M	155.8M	145.6M	347.3M	364.7M
Net Debt	383.2M	(388.7M)	99.6M	169.4M	177.3M	186.2M
Retained Earnings	(1.1B)	(725.4M)	(635.8M)	(406.8M)	(157.1M)	(165.0M)
Accounts Payable	46.2M	39.4M	51.5M	67.3M	108.9M	114.3M
Cash	112.3M	801M	340.8M	262.9M	251.1M	131.9M
Non Current Assets Total	475M	718.5M	1.1B	915.2M	1.6B	1.7B
Non Currrent Assets Other	3.2M	6.4M	4.4M	25M	49.6M	52.1M
Cash And Short Term Investments	670.5M	801M	711.3M	989.3M	1.0B	1.1B
Net Receivables	126.6M	157.1M	185.5M	350M	439.3M	461.3M
Common Stock Shares Outstanding	95.7M	97.8M	97.9M	98.9M	101M	61.8M
Liabilities And Stockholders Equity	1.3B	1.7B	2.1B	2.4B	3.3B	3.4B
Non Current Liabilities Total	103.8M	422M	452.7M	123.2M	364.6M	382.8M
Other Current Assets	160.5M	30.1M	45.5M	79.1M	97.8M	102.7M
Other Stockholder Equity	1.8B	1.8B	2.0B	2.1B	2.4B	2.5B
Total Liab	669.1M	608.5M	698.5M	660.9M	1.0B	1.1B
Property Plant And Equipment Gross	116.3M	127.4M	155.8M	145.6M	430.3M	451.8M
Total Current Assets	831M	1.0B	972.8M	1.5B	1.6B	1.7B
Accumulated Other Comprehensive Income	1.4M	1.8M	(1.7M)	(7.9M)	7M	7.4M
Short Term Debt	408.8M	10.3M	16.5M	169.4M	170.1M	178.6M
Short Term Investments	558.2M	613.9M	370.5M	726.4M	780.5M	819.5M
Other Liab	17.1M	9.7M	12.3M	29.7M	34.2M	24.8M
Other Assets	59.1M	674M	319.5M	330.9M	380.5M	399.6M
Long Term Debt	388.5M	408.8M	317.9M	335.1M	385.4M	404.6M
Common Stock Total Equity	89K	91K	92K	100K	115K	67.8K
Common Stock	89K	91K	92K	100K	115K	69.6K
Property Plant Equipment	33.9M	41.9M	44.6M	58.6M	52.7M	55.4M
Current Deferred Revenue	(46.2M)	(10.3M)	(16.5M)	229.3M	263.7M	276.9M
Net Tangible Assets	228.1M	1.1B	1.4B	1.7B	1.9B	2.0B
Retained Earnings Total Equity	(1.1B)	(725.4M)	(635.8M)	(406.8M)	(366.1M)	(384.4M)
Capital Surpluse	1.8B	1.8B	2.0B	2.1B	2.4B	1.6B
Inventory	17.3M	28M	30.5M	35.1M	38.3M	40.2M
Non Current Liabilities Other	103.8M	104.1M	117.6M	29.7M	10.3M	9.8M
Long Term Investments	299.7M	227.1M	560.7M	401.5M	849.4M	891.9M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

Additional Tools for Neurocrine Stock Analysis

When running Neurocrine Biosciences' price analysis, check to measure Neurocrine Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neurocrine Biosciences is operating at the current time. Most of Neurocrine Biosciences' value examination focuses on studying past and present price action to predict the probability of Neurocrine Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neurocrine Biosciences' price. Additionally, you may evaluate how the addition of Neurocrine Biosciences to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Neurocrine Change In Cash vs End Period Cash Flow Analysis

Change In Cash vs End Period Cash Flow

Change In Cash vs End Period Cash Flow Correlation Analysis

Correlation Coefficient

Change In Cash

End Period Cash Flow

Neurocrine Biosciences fundamental ratios Correlations

Neurocrine Biosciences Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Neurocrine Biosciences fundamental ratios Accounts

Also Currently Popular

Additional Tools for Neurocrine Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net
Total Stockholder Equity	+ 0.99	Total Assets
Non Current Assets Total	+ 0.99	Total Assets
Total Current Assets	+ 0.99	Total Assets
Net Receivables	+ 0.99	Total Stockholder Equity
Accounts Payable	+ 0.99	Property Plant And Equipment Net

Retained Earnings	- 0.57	Short Long Term Debt Total
Common Stock Shares Outstanding	- 0.45	Retained Earnings
Cash	- 0.37	Net Debt
Other Liab	- 0.27	Cash
Other Assets	- 0.18	Net Debt
Other Assets	- 0.14	Other Liab